Healthcare
Live Price
Offline$0.92
+2.22% today
1Y Change
-34.46%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TScan Therapeutics, Inc. (TCRX) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $0.92 and down 34.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +266.7%, EPS growth of +12.3%, a dividend yield of 0.0%. What stands out right now is revenue +266.7%, EPS +12.3%, free cash flow -21.9% with operating margin -1315.4% and ROIC -62.5%. Valuation sits in the middle of the pack at price/sales 6.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TCRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TCRX Max Drawdown
-64.44%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TCRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$10.1M
-25.1% YoY
FY Net Income
-$48.6M
+26.6% YoY
Free Cash Flow
-$58.6M
+17.1% YoY
Revenue Growth
+266.7%
EPS Growth
+12.3%
Gross Margin
85.6%
Net Margin
-1256.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 10M | 3M | 21M | 14M | 10M |
| Gross Profit | 7M | 3M | 21M | 14M | 10M |
| Operating Income | -136M | -135M | -93M | -67M | -49M |
| EBITDA | -133M | -120M | -80M | -60M | -45M |
| Net Income | -130M | -127M | -89M | -66M | -49M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 152M | 179M | 133M | 120M | 161M |
| Total Assets | 229M | 371M | 272M | 199M | 188M |
| Total Liabilities | 106M | 130M | 121M | 100M | 27M |
| Shareholder Equity | 123M | 241M | 151M | 99M | 161M |
| Total Debt | 94M | 97M | 92M | 86M | 6M |
| Net Debt | -58M | -81M | -41M | -34M | -155M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
49M
+26.8% YoY
Capital Expenditures
10M
-135.3% YoY
Free Cash Flow
59M
+17.1% YoY
Key ratios
Gross Margin
85.6%
Operating Margin
-1315.4%
Net Margin
-1256.8%
ROE
-79.4%
Debt / Equity
0.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.